The Latest Cardiac and Vascular News
Olpasiran Reduced Lipoprotein(a) Levels by More Than 95% in Patients With Established ASCVD Amgen is Initiating a Phase 3 Cardiovascular Outcomes Trial Based on These Results Data Simultaneously Published in the New England Journal of Medicine THOUSAND OAKS, Calif. , Nov. 6, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its […]
SHANGHAI , Nov. 7, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM (From Operating Table to Market) innovative platform, today announced the successful close of its latest financing round. The financing was led by YuanBio Venture Capital, other investors includes Orbimed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures (LAV), GaoRong […]
SHANGHAI, Nov. 7, 2022 /PRNewswire/ — From November 1, 2022, Mr. Alan Tsai is promoted to the role of General Manager of Cordis Greater China. He will head the leadership team responsible for strategic planning, business operation and team development for Greater China, the fastest growing area in Asia Pacific. Based in Shanghai, he will report directly to Bryan […]
Six-month primate HAV CABG model demonstrates patency, recellularization and remodeling resembling native blood vessels HAV may address many limitations of current standard of care grafts used in CABG procedure DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered […]
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial Fibrillation Topline Results from the Ongoing Pivotal Phase 3 RESTORE-1 Trial of InRhythm Expected in Early 2024 SAN FRANCISCO, Nov. 07, 2022 (GLOBE NEWSWIRE) — InCarda […]
A new analysis of iRhythm’s mSToPS trial, presented at the American Heart Association, reveals that Zio® XT provided high value from a health economic perspective SAN FRANCISCO, Nov. 06, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that […]
— Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients — — PROMINENT Study Failed to Show CV Risk Reduction Benefit of the Fibrate Class for Statin-Treated High-Risk Patients — DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 07, 2022 […]
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from two additional analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), as well as an analysis of patients hospitalized for heart failure with reduced ejection fraction (HFrEF) from the Get With The Guidelines®-Heart […]
Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30 and 90 Days Following Hospital Discharge THE WOODLANDS, Texas, Nov. 06, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of results from the […]
Forcefield Therapeutics presents positive preclinical data at the 2022 Scientific Sessions of American Heart Association Preclinical data outlining the mechanisms of three proteins shown to restore heart function following acute myocardial infarction (heart attack) presented at AHA Proteins were identified by FunSel technology and developed by Forcefield London UK, 7 November 2022 – Forcefield Therapeutics (“Forcefield”) Ltd, a pioneer of best-in-class therapeutics to protect […]
